BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:VERVE-102 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of VERVE-102\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07839936-1073@assetmemo.bio
DTSTAMP:20261121T005906Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:VERVE-102: Phase 2 readout est. (NCT07839936)
DESCRIPTION:VERVE-102\, phase 2\, Atherosclerotic Cardiovascular Disease.\n
 Study: A Study of VERVE-102 (LY4636581) in Adults With or at High Risk for
  Cardiovascular Disease\nEstimated primary completion: August 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/verve-102#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07839936
URL:https://assetmemo.bio/drug/verve-102#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
